Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981
This study tests a new drug called CKD-981 to see if it can safely reduce knee osteoarthritis symptoms in the short term. Researchers will monitor participants to understand how well the drug works and what side effects, if any, occur during treatment.
Key Objective:The trial is testing whether CKD-981 can provide temporary relief from knee osteoarthritis symptoms.
Who to Consider:People with knee osteoarthritis who are interested in trying a new investigational treatment and are willing to participate in close medical monitoring should consider enrolling.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The purpose of this study is to prove that the temporary symptom improvement effect on knee osteoarthritis using CKD-981
Eligibility Criteria
Inclusion Criteria: * Patients between 40 years and 80 years old * Patients who have experiencing knee pain more than 8 weeks * VAS more than 40 mm * Kellgren and Lawrence grade 2 and 3 in X' ray knee joint Exclusion Criteria: * Previous knee surgery in affected side * Patients with Rheumatoid arthritis, connective tissue disease, Paget's disease * Infection of knee joint * BMI more than 35kg/m2